Longevity & AgingResearch PaperOpen Access

Cellular senescence may drive COPD, asthma and bronchiectasis, and senotherapeutics are being eyed

A narrative review links senescent cells and their inflammatory secretions to COPD, asthma and bronchiectasis. Causality remains unproven in humans.

Wednesday, November 18, 2026 2 views
Published in Int J Mol Sci
a physician reviewing a chest CT scan of lungs on a monitor in a hospital reading room

Summary

This narrative review examines how senescent cells, which stop dividing but keep releasing inflammatory signals, may contribute to three chronic airway diseases: COPD, asthma and bronchiectasis. Smoke, pollution, infection and oxidative stress damage DNA and mitochondria in lung cells, pushing them into senescence. Aged immune cells then fail to clear them, so inflammation and scarring build up. Most cited evidence comes from cell and tissue samples from patients and a few mouse experiments, with no causal human data. Markers used to spot senescent cells are not specific, and it is unclear whether senescence causes these diseases or is a bystander. Senescence may also both suppress and promote cancer. The authors present conventional therapies, antioxidants, serine protease inhibitors and senotherapeutics (drugs aimed at senescent cells) as promising approaches. No clinical-outcome trial results for senotherapeutics in these diseases are reported in the supplied text.

Detailed Summary

Senescent cells are stressed cells that permanently stop dividing yet stay metabolically active, releasing a mix of cytokines, proteases, growth factors and vesicles called the senescence-associated secretory phenotype (SASP). This review asks whether that biology helps explain chronic airway disease. That question matters because the lungs face constant environmental and oxidative insults and rely on effective epithelial repair, and because accelerated lung aging and dysregulated SASP signaling have been reported in COPD and asthma.

The authors ran a narrative (non-systematic) search of PubMed and Google Scholar for 1996 to 2026, prioritizing guidelines, registries, randomized trials and high-quality observational work. They first describe the triggers of senescence: telomere shortening, DNA damage, oncogene activation, oxidative stress and mitochondrial dysfunction. All of these converge on the DNA damage response and the p53/p21 and p16INK4a pathways. Immunosenescence then lets senescent cells accumulate, fueling chronic low-grade inflammation (inflammaging), compensatory immunosuppression and fibrosis.

In COPD, the lung's inflammatory milieu resembles SASP. Alveolar macrophages secrete IL-6, IL-8 and TNF-alpha, and PAI-1 is raised in COPD sputum. Ex vivo endothelial progenitor and epithelial cells from COPD patients show more SA-beta-gal, p16 and p21 than controls. One study suggests interferon signaling sustains senescence in COPD epithelium through cGAS-STING and JAK-STAT. Cigarette smoke also impairs mitophagy in fibroblasts and small airway epithelial cells, and activating mitophagy, particularly via mTOR inhibition, postpones senescence onset. The authors stress these markers are not senescence-specific.

In asthma, a mouse model showed diesel exhaust particles induced senescence, enhanced allergen sensitization and produced airway hyperresponsiveness with eosinophilic inflammation. A computational analysis of human transcriptomes found senescence signatures in asthmatic alveolar macrophages. PPAR-gamma activation reduced both the signature and cytokine output, suggesting partial reversibility (computational and cell-level evidence only). Sputum from severe asthma shows higher ETS2, ETS1 and AURKA. Airway smooth muscle cells from elderly asthmatics show p53/p21 and p16 upregulation with IL-6, IL-8 and fibronectin, linked to remodeling. In bronchiectasis, evidence is sparse: epithelial cells from severe disease show shorter telomeres, higher p21 and lower SIRT1, and a cross-sectional study found lower serum SIRT1 and higher MMP-9.

Senescence plays a dual role in cancer. It is tumor-suppressive through cell-cycle arrest, yet SASP factors such as IL-6, IL-8 and VEGF can promote tumors in experimental models. The authors note that uncertainty remains about whether chronic SASP in COPD favors tumor suppression or tumor promotion. They also flag key gaps: no specific, stable senescence biomarker exists, and longitudinal, age-matched studies are needed to determine whether senescence is causal or an epiphenomenon. The authors present conventional therapies, antioxidants, serine protease inhibitors and novel senotherapeutic strategies as promising therapeutic approaches. The supplied text reports no clinical-outcome trial results for senotherapeutics in COPD, asthma or bronchiectasis, so their benefit in these diseases remains to be shown.

Key Findings

  • Mechanism (human ex vivo): COPD epithelial and endothelial progenitor cells show higher SA-beta-gal, p16 and p21 than control cells; markers are not senescence-specific.
  • Mechanism (human ex vivo): interferon signaling in COPD epithelium may sustain senescence via cGAS-STING and JAK-STAT; causality not shown.
  • Mouse model: diesel exhaust particle-induced senescence enhanced allergen sensitization, airway hyperresponsiveness and eosinophilic inflammation.
  • Computational human transcriptomic data: asthmatic alveolar macrophages carry senescence signatures; PPAR-gamma activation attenuated signature and cytokine output (function not tested in patients).
  • Ex vivo airway smooth muscle from elderly asthmatics showed p53/p21 and p16 upregulation plus higher IL-6, IL-8 and fibronectin versus age-matched controls, tied to airway remodeling.
  • Bronchiectasis epithelium showed shorter telomeres, higher p21 and lower SIRT1; a cross-sectional study found lower serum SIRT1 and higher MMP-9, but evidence is scarce and non-causal.
  • No lifespan or clinical-outcome data for senotherapeutics in airway disease; the senescence-cancer relationship is unresolved (suppressive vs promoting).

Methodology

This is a narrative review, not a systematic one. The authors searched PubMed and Google Scholar (1996 to 2026) with terms combining cellular senescence, COPD, asthma, bronchiectasis and SASP, prioritizing guidelines, registries, randomized trials and high-quality observational studies. No pooled analysis, formal risk-of-bias assessment or sample-size synthesis was done. Cited evidence is mostly ex vivo human cells, sputum and serum samples, computational transcriptomics and a few mouse models.

Study Limitations

The review is narrative with no systematic selection, so bias is possible. The authors note no single senescence marker is specific or stable, much evidence is cross-sectional or ex vivo, and bronchiectasis literature is limited. It remains unclear whether senescence is causal or a bystander. The excerpt supplied was truncated, and no conflicts of interest were visible in it.

Enjoyed this summary?

Get the latest longevity research delivered to your inbox every week.

Enter your email to subscribe: